Celldex Therapeutics (NASDAQ:CLDX) executives highlighted recent clinical progress and upcoming catalysts during a discussion at the Leerink Partners Global Healthcare Conference, with a major focus on the company’s Phase III program in chronic spontaneous urticaria (CSU) for barzolvolimab. Execution milestones and upcoming readouts President and CEO Anthony Marucci described 2025 as “a year of execution,” […]